The International Immuno-Oncology Biomarker Working Group has launched a global survey on the potential use of Tumor Infiltrating Lymphocytes (TILs) for future trial designs and use in daily practice.
The International Immuno-Oncology Biomarker Working Group (also called the TILs-WG) has launched a global survey on the potential use of Tumor Infiltrating Lymphocytes (TILs) for future trial designs and use in daily practice.
This initiative was triggered by high level discussions at BIG and other trial-groups on the design of de-escalation of systemic chemotherapy and immunotherapy-trials using TILs, on discussions within the pathology community on how best to integrate TILs in daily practice and on patients’ input that knowing on the TILs may be useful for them to know on. Hence this survey was developed with specific questions for pathologists, oncologists, patients and industry.
This survey takes less than 10min of your time and can be found on the Homepage website of the TILs-WG www.tilsinbreastcancer.org; click on the Blue Bar stating “Your Opinion is Important. Please click HERE to tell how YOU think the TILs should be used!”. Once done, please do NOT forget to click “SEND”.
Your contribution will be treated anonymous and will not be disclosed in public. The results of this survey will be made public after summer 2021.
Many thanks for your consideration,